IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
IN8bio (NASDAQ: INAB) ha annunciato che presenterà nuovi dati preclinici sulla sua innovativa piattaforma di engagers per cellule T gamma-delta (γδ) al AACR Annual Meeting 2025 a Chicago. La presentazione metterà in evidenza l'approccio innovativo dell'azienda all'immunoterapia contro il cancro, combinando le capacità innate di riconoscimento tumorale delle cellule T gamma-delta con engagers bispecifici.
La ricerca si concentra sul superamento delle limitazioni delle attuali terapie basate su engagers CD-3, sfruttando le proprietà uniche delle cellule T gamma-delta, tra cui residenza nei tessuti, fagocitosi e bassa secrezione di IL-6. I primi risultati in AML e B-ALL dimostrano il potenziale per risposte immunitarie mirate contro più antigeni.
La presentazione del poster intitolata 'Una nuova piattaforma di engagers per cellule T gamma-delta per l'immunoterapia contro il cancro' (Abstract #7321) sarà presentata mercoledì 30 aprile 2025, dalle 9:00 alle 12:00 CT.
IN8bio (NASDAQ: INAB) ha anunciado que presentará nuevos datos preclínicos sobre su innovadora plataforma de engagers de células T gamma-delta (γδ) en la AACR Annual Meeting 2025 en Chicago. La presentación destacará el enfoque innovador de la empresa hacia la inmunoterapia contra el cáncer, combinando las capacidades innatas de reconocimiento tumoral de las células T gamma-delta con engagers bispecíficos.
La investigación se centra en superar las limitaciones de las terapias actuales basadas en engagers CD-3, aprovechando las propiedades únicas de las células T gamma-delta, que incluyen residencia en tejidos, fagocitosis y baja secreción de IL-6. Los primeros hallazgos en AML y B-ALL demuestran el potencial para respuestas inmunitarias dirigidas contra múltiples antígenos.
La presentación del póster titulada 'Una nueva plataforma de engagers de células T gamma-delta para la inmunoterapia contra el cáncer' (Abstract #7321) se presentará el miércoles 30 de abril de 2025, de 9:00 AM a 12:00 PM CT.
IN8bio (NASDAQ: INAB)는 시카고에서 열리는 AACR Annual Meeting 2025에서 혁신적인 감마-델타 (γδ) T 세포 인게이저 플랫폼에 대한 새로운 전임상 데이터를 발표할 것이라고 발표했습니다. 이 발표는 암 면역 요법에 대한 회사의 혁신적인 접근 방식을 선보이며, 감마-델타 T 세포의 고유한 종양 인식 능력과 이중 특이성 인게이저를 결합합니다.
이 연구는 고유한 조직 거주, 식세포 작용 및 낮은 IL-6 분비를 포함한 감마-델타 T 세포의 독특한 특성을 활용하여 현재 CD-3 기반 인게이저 요법의 한계를 극복하는 데 중점을 두고 있습니다. AML 및 B-ALL의 초기 결과는 여러 항원에 대한 표적 면역 반응의 가능성을 보여줍니다.
'암 면역 요법을 위한 새로운 감마-델타 T 세포 인게이저 플랫폼' (초록 #7321)이라는 제목의 포스터 발표는 2025년 4월 30일 수요일 오전 9시부터 오후 12시까지 CT에 진행됩니다.
IN8bio (NASDAQ: INAB) a annoncé qu'elle présentera de nouvelles données précliniques sur sa plateforme novatrice d'engagers de cellules T gamma-delta (γδ) lors de la AACR Annual Meeting 2025 à Chicago. La présentation mettra en avant l'approche innovante de l'entreprise en matière d'immunothérapie contre le cancer, combinant les capacités innées de reconnaissance tumorale des cellules T gamma-delta avec des engagers bispécifiques.
La recherche se concentre sur le surpassement des limitations des thérapies actuelles basées sur des engagers CD-3, en tirant parti des propriétés uniques des cellules T gamma-delta, y compris la résidence tissulaire, la phagocytose et la faible sécrétion d'IL-6. Les premiers résultats en AML et B-ALL démontrent le potentiel de réponses immunitaires ciblées contre plusieurs antigènes.
La présentation de l'affiche intitulée 'Une nouvelle plateforme d'engagers de cellules T gamma-delta pour l'immunothérapie contre le cancer' (Résumé #7321) sera présentée le mercredi 30 avril 2025, de 9h00 à 12h00 CT.
IN8bio (NASDAQ: INAB) hat angekündigt, dass es neue präklinische Daten zu seiner neuartigen Gamma-Delta (γδ) T-Zell-Engager-Plattform auf dem AACR Annual Meeting 2025 in Chicago präsentieren wird. Die Präsentation wird den innovativen Ansatz des Unternehmens zur Krebsimmuntherapie hervorheben, der die angeborenen Tumorerkennungskapazitäten der Gamma-Delta-T-Zellen mit bispezifischen Engagern kombiniert.
Die Forschung konzentriert sich darauf, die Einschränkungen der aktuellen CD-3-basierten Engager-Therapien zu überwinden, indem sie die einzigartigen Eigenschaften der Gamma-Delta-T-Zellen nutzt, einschließlich Geweberesidenz, Phagozytose und niedriger IL-6-Sekretion. Erste Ergebnisse bei AML und B-ALL zeigen das Potenzial für gezielte Immunantworten gegen mehrere Antigene.
Die Posterpräsentation mit dem Titel 'Eine neuartige Gamma-Delta-T-Zell-Engager-Plattform für die Krebsimmuntherapie' (Abstract #7321) wird am Mittwoch, den 30. April 2025, von 9:00 bis 12:00 Uhr CT präsentiert.
- Development of potentially breakthrough next-generation cancer immunotherapy platform
- Early positive preclinical findings in multiple cancer types (AML and B-ALL)
- Platform demonstrates capability to target multiple cancer antigens
- Technology still in early preclinical stage
- No clinical efficacy data available yet
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.
“T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the limitations of current CD-3 based engager therapies,” said William Ho, CEO, and co-founder of IN8bio. Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the capacity for significant cell expansion and the specificity of bispecific engagers to drive a potent, targeted immune response against multiple target antigens. These early findings in AML and B-ALL support our broader strategy to harness the unique biology of these cells across a range of cancers.”
AACR Poster Presentation Details
Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy
Abstract Presentation Number: 7321 (Poster Board 7)
Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies
Session Date and Time: Wednesday, April 30, 2025, 9:00 AM – 12:00 PM CT
For more details visit: www.aacr.org/meeting/aacr-annual-meeting-2025/abstracts.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
What new technology will IN8bio (INAB) present at AACR 2025?
What advantages does IN8bio's gamma-delta T cell platform offer over current therapies?
Which cancer types has IN8bio's gamma-delta T cell platform shown early results in?
When and where will IN8bio present their gamma-delta T cell engager data?
